Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 12/20 | 0.58 |
| ▸ | KDR | P35968 | 6/20 | 0.51 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.42 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.42 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.42 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13336898 | 0.85 | FGFR3 (0.58) | FLT3KDRFGFR3 | |
| SCHEMBL13336414 | 0.82 | KDR (0.67) | FLT3KDRFGFR3 | |
| SCHEMBL14144061 | 0.82 | KDR (0.70) | FLT3KDRFGFR3PIK3CA | |
| SCHEMBL1015853 | 0.79 | CYP3A4 (0.53) | — | |
| SCHEMBL3322667 | 0.78 | FGFR3 (0.73) | KDRFGFR3 | |
| Formic Acid SCHEMBL3324113 | 0.77 | KDR (0.66) | FLT3KDRFGFR3 | |
| SCHEMBL13336906 | 0.77 | FGFR3 (0.59) | FLT3KDRFGFR3 | |
| SCHEMBL16588375 | 0.76 | FLT3 (0.74) | FLT3KDRFGFR3 | |
| SCHEMBL13336707 | 0.74 | FLT3 (1.00) | FLT3KDRFGFR3 | |
| SCHEMBL20903378 | 0.74 | KDR (0.71) | FLT3KDRFGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114941-B1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2015-03-25 | — | — | EP | disclosed |